Compare CAVA Group Inc (CAVA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CAVA Group Inc vs GeneDx Holdings Corp — how do they compare? CAVA Group Inc trades at $72.71 (market cap $8.15B), while GeneDx Holdings Corp trades at $63.81 (market cap $1.85B). The key difference: CAVA Group Inc is far larger — about 4.4× GeneDx Holdings Corp's market cap, and CAVA Group Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| CAVA | WGS | |
|---|---|---|
Market Cap | $8.15B | $1.85B |
Sector | Consumer Cyclical | Technology |
52-Week High | $97.39 | $167.51 |
52-Week Low | $43.59 | $34.51 |
Enterprise Value | $8.25B | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $72.54, up 0.5% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong revenue growth and expansion momentum, but faces high valuation multiples and margin pressures. Recent news highlights aggressive store openings and technology investments driving traffic, though the stock has experienced volatility amid market fluctuations.
Outlook remains growth-focused with analyst consensus bullish, targeting $94.73, but risks include elevated P/E of 134.56, competitive pressures, and potential margin compression from expansion costs. The stock offers upside if execution continues, but requires careful monitoring of profitability trends.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
